Blood product corporation SK Plasma will exclusively sell the blood cancer treatment drug Velcade (ingredient name: bortezomib) from global pharmaceutical corporation Janssen in South Korea. Janssen is the pharmaceutical division of the global corporation Johnson & Johnson (J&J).
SK Plasma noted on the 16th that it has signed an exclusive sales agreement for Velcade (ingredient name: bortezomib) with Korea Janssen, which treats multiple myeloma and mantle cell lymphoma. According to the agreement, Korea Janssen will produce and supply Velcade products, while SK Plasma will handle domestic distribution and marketing.
This agreement has expanded SK Plasma's product lineup for blood cancer treatments. The company is currently selling a treatment for myelodysplastic syndromes and acute myeloid leukemia, Dakogen (ingredient name: decitabine), under an exclusive contract with Korea Janssen that was signed last year.
Kim Seung-joo, CEO of SK Plasma, said, "This agreement allows us to strengthen our oncology portfolio while providing a medication that has become the standard treatment for multiple myeloma patients. We will continue to develop and introduce various medications to contribute to improving patients' quality of life."